Nexstim Plc financial statements release 2019
Helsinki, Finland: 28 February 2020 – Nexstim Plc (NXTMH:HEX, NXTMS:STO), today provides its financial statements for the full year 2019 (1 January–31 December 2019) and H2 2019 (1 July-31 December 2019).
Highlights, July – December 2019
- The NBT® system active commercial installed base grew to a total of 23 systems at end of December 2019, of which the US NBT® system installed base was a total of 10 systems and in Europe and rest of the world a total of 13 NBT® systems.
- Nexstim received a medical device license from Health Canada, which allows Nexstim to start marketing and commercial distribution of the NBT® system for the treatment of Major Depressive Disorder (MDD) in Canada.
- H2 revenues amounted to EUR 2.1 million (2018: EUR 1.6 million), an increase of 33.8 percent year-on-year.
- H2 NBT revenues amounted to EUR 0.9 million (2018: EUR 0.4 million), an increase of 110.4 percent year-on-year.
More info on Nexstim‘s website.